RU2018117557A - Применение долгодействующих пептидов glp-1 - Google Patents
Применение долгодействующих пептидов glp-1 Download PDFInfo
- Publication number
- RU2018117557A RU2018117557A RU2018117557A RU2018117557A RU2018117557A RU 2018117557 A RU2018117557 A RU 2018117557A RU 2018117557 A RU2018117557 A RU 2018117557A RU 2018117557 A RU2018117557 A RU 2018117557A RU 2018117557 A RU2018117557 A RU 2018117557A
- Authority
- RU
- Russia
- Prior art keywords
- use according
- semaglutide
- administered
- phosphate buffer
- peptides
- Prior art date
Links
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 title 1
- 230000007774 longterm Effects 0.000 title 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 6
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 claims 6
- 229950011186 semaglutide Drugs 0.000 claims 6
- 108010060325 semaglutide Proteins 0.000 claims 6
- 239000008363 phosphate buffer Substances 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 239000007864 aqueous solution Substances 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 238000010254 subcutaneous injection Methods 0.000 claims 2
- 239000007929 subcutaneous injection Substances 0.000 claims 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims 1
- 235000019799 monosodium phosphate Nutrition 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical group [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12174535.0 | 2012-07-01 | ||
| EP12174535 | 2012-07-01 | ||
| US201261694837P | 2012-08-30 | 2012-08-30 | |
| US61/694,837 | 2012-08-30 | ||
| US201261708162P | 2012-10-01 | 2012-10-01 | |
| US61/708,162 | 2012-10-01 | ||
| EP12186781 | 2012-10-01 | ||
| EP12186781.6 | 2012-10-01 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101826A Division RU2657573C2 (ru) | 2012-07-01 | 2013-06-21 | Применение долгодействующих пептидов glp-1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2023131642A Division RU2023131642A (ru) | 2012-07-01 | 2023-12-01 | Применение долгодействующих пептидов glp-1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2018117557A true RU2018117557A (ru) | 2019-03-22 |
| RU2018117557A3 RU2018117557A3 (cg-RX-API-DMAC10.html) | 2021-08-20 |
Family
ID=65858459
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2018117557A RU2018117557A (ru) | 2012-07-01 | 2013-06-21 | Применение долгодействующих пептидов glp-1 |
| RU2015101826A RU2657573C2 (ru) | 2012-07-01 | 2013-06-21 | Применение долгодействующих пептидов glp-1 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015101826A RU2657573C2 (ru) | 2012-07-01 | 2013-06-21 | Применение долгодействующих пептидов glp-1 |
Country Status (17)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| AU2012241894B2 (en) | 2011-04-12 | 2015-12-03 | Novo Nordisk A/S | Double-acylated GLP-1 derivatives |
| KR102072202B1 (ko) | 2012-03-22 | 2020-01-31 | 노보 노르디스크 에이/에스 | Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조 |
| WO2013189988A1 (en) | 2012-06-20 | 2013-12-27 | Novo Nordisk A/S | Tablet formulation comprising a peptide and a delivery agent |
| HUE049152T2 (hu) | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
| RS58039B1 (sr) | 2013-05-02 | 2019-02-28 | Novo Nordisk As | Oralno doziranje glp-1 jedinjenja |
| KR102127624B1 (ko) * | 2014-10-16 | 2020-06-29 | 얀마 파워 테크놀로지 가부시키가이샤 | 작업 차량 |
| GB201621987D0 (en) * | 2016-12-22 | 2017-02-08 | Archer Virgil L See Archer Sheri A Arecor Ltd | Novel composition |
| DE102017106216A1 (de) * | 2017-03-22 | 2018-09-27 | Amw Gmbh | Extrudierte Depotform zur anhaltenden Wirkstofffreisetzung |
| BR112020002804A2 (pt) | 2017-08-24 | 2020-07-28 | Novo Nordisk A/S | composição farmacêutica líquida, e, kit |
| CA3078652A1 (en) * | 2017-10-12 | 2019-04-18 | Novo Nordisk A/S | Semaglutide in medical therapy |
| GB201720187D0 (en) * | 2017-12-04 | 2018-01-17 | Imperial Innovations Ltd | Novel Compounds |
| AR114353A1 (es) | 2018-02-02 | 2020-08-26 | Novo Nordisk As | Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico |
| TWI705820B (zh) | 2018-06-22 | 2020-10-01 | 美商美國禮來大藥廠 | Gip/glp1促效劑組合物 |
| WO2020028907A1 (en) * | 2018-08-03 | 2020-02-06 | Brown University | Compositions and methods for improving the bioavailability of glp1 and analogues thereof |
| WO2020072306A1 (en) * | 2018-10-01 | 2020-04-09 | Amgen Inc. | Methods for reducing aggregation of bispecific antibodies |
| CA3131689A1 (en) * | 2019-02-26 | 2020-09-03 | Twist Bioscience Corporation | Variant nucleic acid libraries for glp1 receptor |
| WO2020180534A1 (en) | 2019-03-01 | 2020-09-10 | President And Fellows Of Harvard College | Methods and compositions for protein delivery |
| CA3154744A1 (en) | 2019-11-06 | 2021-05-14 | Sarah FRIEDRICH | Glp-1 receptor agonists in dementia |
| AU2020418207A1 (en) * | 2019-12-30 | 2022-08-25 | Gan & Lee Pharmaceuticals Co., Ltd. | Long-acting GLP-1 compound |
| TW202228762A (zh) | 2020-01-30 | 2022-08-01 | 美商美國禮來大藥廠 | 提派肽(tirzepatide)之治療用途 |
| US12605426B2 (en) | 2020-02-14 | 2026-04-21 | G2Gbio, Inc. | Pharmaceutical comprising sustained-release microspheres including GLP-1 analogue or pharmaceutically acceptable salt thereof |
| IL294521A (en) * | 2020-02-18 | 2022-09-01 | Novo Nordisk As | glp-1 compounds and their uses |
| CN112768087A (zh) * | 2020-12-23 | 2021-05-07 | 吉林大学 | 利用孟德尔随机化方法验证索马鲁肽口服制剂预防二型糖尿病的用途 |
| EP4359074A4 (en) * | 2021-06-24 | 2025-06-04 | Gila Therapeutics, Inc. | METHODS AND KITS FOR INDUCTING SATOURAGE AND TREATMENT OF METABOLIC DISEASES |
| US11865213B2 (en) * | 2021-07-05 | 2024-01-09 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| US12514908B2 (en) | 2021-07-05 | 2026-01-06 | Mapi Pharma Ltd. | Semaglutide depot systems and use thereof |
| SI4408840T1 (sl) | 2021-09-27 | 2025-12-31 | Terns Pharmaceuticals, Inc. | Benzimidazolne karboksilne kisline kot agonisti GLP-1R |
| US12024507B2 (en) | 2021-10-25 | 2024-07-02 | Terns Pharmaceuticals, Inc. | Compounds as GLP-1R agonists |
| CA3237751A1 (en) | 2021-11-10 | 2023-05-19 | Tyler Brown | Ionic liquid compositions |
| CN114874314B (zh) * | 2021-12-28 | 2022-11-11 | 北京惠之衡生物科技有限公司 | 一种高表达glp-1类似物的重组工程菌及其构建方法 |
| AU2023224854A1 (en) | 2022-02-23 | 2024-10-03 | Terns Pharmaceuticals, Inc. | Compounds as glp-1r agonists |
| WO2023225370A1 (en) * | 2022-05-19 | 2023-11-23 | Vault Bioventures, Inc. | Obesity treatment and prevention methods |
| CN121001710A (zh) | 2022-12-30 | 2025-11-21 | 阿尔吉法玛公司 | 提高口服多肽治疗剂的全身生物利用度的组合物和方法 |
| PE20252787A1 (es) | 2023-04-07 | 2025-12-22 | Terns Pharmaceuticals Inc | Combinacion que comprende un agonista de thr-beta y un agonista de glp-1r para su uso en el tratamiento de un trastorno hepatico o una enfermedad cardiometabolica |
| US20260007869A1 (en) | 2023-06-23 | 2026-01-08 | Vaxess Technologies, Inc. | Microneedle array patches (maps), systems, and methods for manufacturing and using same |
| EP4750447A1 (en) | 2023-07-24 | 2026-06-03 | The Board of Trustees of the Leland Stanford Junior University | Compositions and methods for delivery of therapeutic peptides |
| WO2025165146A1 (ko) * | 2024-01-29 | 2025-08-07 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드 또는 티르제파타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용으로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| KR102930984B1 (ko) * | 2024-01-29 | 2026-02-25 | 주식회사 티온랩테라퓨틱스 | 세마글루타이드의 개선된 의료 요법 제공을 위한 비만 및 당뇨 치료용로써, 소수성 이온 페어링 겔레이션을 통한 초기 방출이 제어된 데포 조성물 및 이의 제조방법 |
| WO2026046328A1 (en) * | 2024-08-30 | 2026-03-05 | Beijing Ql Biopharmaceutical Co., Ltd. | Dosing regimen of glp-1 conjugates |
| CN118845644B (zh) * | 2024-09-27 | 2025-01-17 | 杭州信海医药科技有限公司 | 一种司美格鲁肽注射液的制备方法 |
| GB202418179D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
| GB202418172D0 (en) | 2024-12-11 | 2025-01-22 | Algipharma As | Compositions and methods |
| WO2026148333A2 (en) * | 2025-01-06 | 2026-07-09 | Sparrow Pharmaceuticals, Inc. | Methods and compositions |
| WO2026161748A1 (en) | 2025-01-23 | 2026-07-30 | The Board Of Trustees Of The Leland Stanford Junior University | Dynamic hydrogels for delivery of therapeutic peptides |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK39892D0 (da) | 1992-03-25 | 1992-03-25 | Bernard Thorens | Peptid |
| DE122009000079I2 (de) | 1996-08-30 | 2011-06-16 | Novo Nordisk As Novo Alle | Glp-1 derivate |
| ES2298378T3 (es) | 2001-06-28 | 2008-05-16 | Novo Nordisk A/S | Formulacion estable de glp-1 modificado. |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| KR101243648B1 (ko) | 2003-11-20 | 2013-03-14 | 노보 노르디스크 에이/에스 | 제조 및 주사 장치용에 최적인 프로필렌 글리콜 함유펩티드 제제 |
| RU2413530C9 (ru) * | 2004-11-12 | 2021-05-18 | Ново Нордиск А/С | Стабильные препараты инсулинотропных пептидов |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| RU2409349C2 (ru) * | 2006-04-14 | 2011-01-20 | Маннкайнд Корпорейшн | Фармацевтические композиции, содержащие глюкагонподобный пептид(glp-1) |
| EP2121897A4 (en) | 2007-03-20 | 2010-03-31 | Nippon Kayaku Kk | METHOD FOR MONITORING THE DRUG EFFECT ON DIABETES PATIENTS USING AN ASSAY FOR 1,5-ANHYDRO-D-GLUCITOL |
| EP2514406A1 (en) | 2007-06-01 | 2012-10-24 | Novo Nordisk A/S | Spontaneously dispersible preconcentrates including a peptide drug in a solid or semisolid carrier |
| US20100292133A1 (en) | 2007-09-05 | 2010-11-18 | Novo Nordisk A/S | Truncated glp-1 derivaties and their therapeutical use |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| US20100317057A1 (en) | 2007-12-28 | 2010-12-16 | Novo Nordisk A/S | Semi-recombinant preparation of glp-1 analogues |
| HUE031900T2 (en) | 2008-12-10 | 2017-08-28 | Glaxosmithkline Llc | Pharmaceutical compositions containing Albiglutide |
| WO2010092163A2 (en) * | 2009-02-13 | 2010-08-19 | Boehringer Ingelheim International Gmbh | Antidiabetic medications |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| MX341025B (es) * | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
| CN102203130B (zh) | 2010-08-06 | 2014-06-25 | 贝达药业股份有限公司 | Glp-1衍生物及其应用 |
| MX377589B (es) | 2010-12-16 | 2025-03-10 | Novo Nordisk As | Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico. |
| US20130035281A1 (en) | 2011-02-09 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CN102718858B (zh) | 2011-03-29 | 2014-07-02 | 天津药物研究院 | 胰高血糖素样肽-1类似物单体、二聚体及其制备方法与应用 |
| WO2012136790A1 (en) | 2011-04-07 | 2012-10-11 | Glaxo Group Limited | Compositions comprising fusion proteins or conjugates with an improved half -life |
| CN102229668A (zh) | 2011-06-03 | 2011-11-02 | 浙江贝达药业有限公司 | 一种glp-1衍生物及其应用 |
| US20140220134A1 (en) | 2011-06-24 | 2014-08-07 | Astrazeneca Pharamceuticals LP | Method for treating diabetes with extended release formulation of glp-1 receptor agonists |
| HUE049152T2 (hu) | 2012-07-01 | 2020-09-28 | Novo Nordisk As | Hosszantartó hatású GLP-1 peptidek alkalmazása |
-
2013
- 2013-06-21 HU HUE13737808A patent/HUE049152T2/hu unknown
- 2013-06-21 AU AU2013286177A patent/AU2013286177B2/en active Active
- 2013-06-21 MX MX2014014946A patent/MX366405B/es active IP Right Grant
- 2013-06-21 EP EP20157813.5A patent/EP3689365B1/en active Active
- 2013-06-21 MX MX2019008148A patent/MX376058B/es active IP Right Grant
- 2013-06-21 WO PCT/EP2013/063004 patent/WO2014005858A1/en not_active Ceased
- 2013-06-21 PL PL20157813.5T patent/PL3689365T3/pl unknown
- 2013-06-21 PL PL13737808.9T patent/PL2866825T3/pl unknown
- 2013-06-21 RS RS20200684A patent/RS60432B1/sr unknown
- 2013-06-21 BR BR112014032938A patent/BR112014032938A2/pt not_active Application Discontinuation
- 2013-06-21 HR HRP20251088TT patent/HRP20251088T1/hr unknown
- 2013-06-21 RS RS20250936A patent/RS67258B1/sr unknown
- 2013-06-21 CA CA2877056A patent/CA2877056A1/en not_active Abandoned
- 2013-06-21 HU HUE20157813A patent/HUE072859T2/hu unknown
- 2013-06-21 PT PT137378089T patent/PT2866825T/pt unknown
- 2013-06-21 ES ES20157813T patent/ES3041720T3/es active Active
- 2013-06-21 EP EP13737808.9A patent/EP2866825B1/en not_active Revoked
- 2013-06-21 US US14/409,493 patent/US9764003B2/en active Active
- 2013-06-21 RU RU2018117557A patent/RU2018117557A/ru unknown
- 2013-06-21 DK DK13737808.9T patent/DK2866825T3/da active
- 2013-06-21 SI SI201331733T patent/SI2866825T1/sl unknown
- 2013-06-21 ES ES13737808T patent/ES2796839T3/es active Active
- 2013-06-21 EP EP24175788.9A patent/EP4406593A3/en active Pending
- 2013-06-21 HR HRP20200889TT patent/HRP20200889T1/hr unknown
- 2013-06-21 RU RU2015101826A patent/RU2657573C2/ru active
- 2013-06-21 JP JP2015519000A patent/JP6059802B2/ja active Active
-
2014
- 2014-12-05 MX MX2020010693A patent/MX2020010693A/es unknown
-
2017
- 2017-07-21 US US15/656,042 patent/US10335462B2/en active Active
-
2018
- 2018-04-10 AU AU2018202504A patent/AU2018202504B2/en active Active
-
2020
- 2020-04-16 AU AU2020202573A patent/AU2020202573B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20251088T1 (hr) | Upotreba dugodjelujućih peptida glp‑1 | |
| HRP20200072T1 (hr) | Načini doziranja za spojeve klase ehinokandina | |
| EA201492021A1 (ru) | Антительный состав | |
| EA201270167A1 (ru) | Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения | |
| MX2012002082A (es) | Terapia de acetato de glatiramero de baja frecuencia. | |
| MX392388B (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe) | |
| CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
| PH12015501931A1 (en) | Treatment of diabetes mellitus by long-acting formulations of insulins | |
| FI3229828T3 (fi) | Glargiini-insuliinin/liksisenatidin vakiosuhteinen formulaatio | |
| EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
| MY204827A (en) | Semaglutide in medical therapy | |
| EA201201617A1 (ru) | Применение метморфина в комбинации с активатором глюкокиназы и композиции, содержащие метморфин и активатор глюкокиназы | |
| BR112014003529A2 (pt) | combinações de corroles e estatinas | |
| RU2023131642A (ru) | Применение долгодействующих пептидов glp-1 | |
| EA201291463A1 (ru) | Составы для инфузии лантибиотиков типа b | |
| EA201491841A1 (ru) | Состав эсмолола для парентерального введения | |
| MX383557B (es) | Formulaciones inyectables de paracetamol. | |
| RU2013153993A (ru) | Способ коррекции тиреоидного статуса племенных крольчих-первокролок в эндемичных зонах путем комбинированного применения йода и селена | |
| RU2012123182A (ru) | Способ коррекции психического состояния пациентов и антиоксидантого статуса при органическом расстройстве личности | |
| RU2011101481A (ru) | Способ профилактики острой декомпрессионной болезни | |
| RU2013142835A (ru) | Способ лечения ишемического инсульта | |
| RU2013143983A (ru) | Способ коррекции иммунной недостаточности у инфицированного вирусом лейкоза крупного рогатого скота | |
| EA201500065A1 (ru) | Инъецируемый супернасыщенный раствор ацетаминофена для спинального введения | |
| RU2013119140A (ru) | Способ лечения вегетососудистой дистонии у детей и подростков | |
| RU2010103147A (ru) | Способ нормализации углеводного обмена |